AGWCA
HALO icon

Annis Gardner Whiting Capital Advisors’s Halozyme HALO Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$539 – 1360
2025
Q4 		$539 Buy
+8
New +$538 ﹤0.01% 1106

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's HALO Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Halozyme (HALO) in Q1 2026, closing a stake of 8 shares — an estimated $539 sold.

Annis Gardner Whiting Capital Advisors first reported a position in HALO in Q4 2025 and held it in 1 quarter. The position peaked at $539 in Q4 2025. 637 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 8 Halozyme shares in Q1 2026, an estimated $539.
  • Annis Gardner Whiting Capital Advisors first reported a position in Halozyme in Q4 2025 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's Halozyme position peaked at $539 in Q4 2025.
  • 637 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.